ADMS:NSD-Adamas Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 0.38B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Adamas Pharmaceuticals Inc (ADMS) Stock Analysis:
Based on the Adamas Pharmaceuticals Inc stock forecasts from 5 analysts, the average analyst target price for Adamas Pharmaceuticals Inc is USD 0.00 over the next 12 months. Adamas Pharmaceuticals Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Adamas Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Adamas Pharmaceuticals Inc’s stock price was USD 0.00. Adamas Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

About

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Pa ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-20 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

-0.03 (-0.04%)

USD6.91B 16.03 37.25
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
ITCI Intra-Cellular Therapies Inc

+0.13 (+0.34%)

USD3.83B N/A N/A
TLRY Tilray Inc

-0.05 (-0.84%)

USD3.07B N/A N/A
CGC Canopy Growth Corporation

-0.08 (-1.05%)

USD3.06B N/A N/A
PCRX Pacira BioSciences Inc

-0.26 (-0.40%)

USD2.86B 47.35 19.70
IRWD Ironwood Pharmaceuticals Inc

-0.27 (-2.41%)

USD1.84B 3.47 7.38
SUPN Supernus Pharmaceuticals Inc

+0.07 (+0.24%)

USD1.55B 19.33 9.45

ETFs Containing ADMS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.04% 43% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.04% 41% F 13% F
Risk Return Profile  
Volatility (Standard Deviation) 63.49% 33% F 26% F
Risk Adjusted Return -9.52% 48% F 18% F
Market Capitalization 0.38B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 34.18 N/A N/A N/A N/A
Price / Cash Flow Ratio -7.42 N/A N/A N/A N/A
EV/EBITDA 0.11 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -42.71% N/A N/A N/A N/A
Return on Assets -15.40% N/A N/A N/A N/A
Debt to Equity Ratio -252.74% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.42 N/A N/A N/A N/A
Short Percent 1.17% N/A N/A N/A N/A
Beta 2.82 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.